Andreas Halvorsen: portfolio of Viking Global Investors

Andreas Halvorsen leads Viking Global Investors, a hedge fund that analyzes stocks worldwide and combines long and short positions.

Source: 13F filing with the US Securities and Exchange Commission dated Nov 14, 2022. It shows positions at quarter end and is filed up to 45 days later – today the positions may be several months old. It covers only securities traded on US exchanges, without short positions; securities traded only abroad and cash are not included.

You are looking at Q3 2022. Go to the latest filing (Q3 2026)

21.6B USDQ3 2022
Total value of stock positions
21.6B USD
Positions
87
Share of the ten largest
37.9%

The ten largest positions Q3 2022

  1. Elevance Health 4.9%▲ +59.6%
  2. Amazon 4.9%▲ +14.6%
  3. Visa Inc. 4.4%▲ +109.2%
  4. McKesson Corporation 4.1%▲ +60.5%
  5. Microsoft 3.8%▲ +18.5%
  6. GE Aerospace 3.7%▲ +47.1%
  7. Meta Platforms 3.4%▲ +86.7%
  8. Chubb Limited 3.0%▼ −4.8%
  9. Boston Scientific 2.9%▲ +10.3%
  10. Brookfield Asset Mgmt Inc 2.8%▲ +21.6%
Total value of stock positions per quarter, Q2 2013 to Q3 2026 (peak 38.5B USD).
Choose a quarter (54 filings)

All positions Q3 2022

Positions Q3 2022 per 13F filing, 50 of 87
Symbol Weight Shares Reported value Change Held since
AMZN Amazon 4.9% 9,286,956 1.0B USD +14.6% increased Q2 2015 30 quarters
MSFT Microsoft 3.8% 3,510,344 817.6M USD +18.5% increased Q2 2016 26 quarters
V Visa Inc. 4.4% 5,346,584 949.8M USD +109.2% increased Q3 2016 25 quarters
Catalent Inc 0.6% 1,673,755 121.1M USD −14.7% reduced Q1 2018 19 quarters
BSX Boston Scientific 2.9% 16,162,921 626.0M USD +10.3% increased Q3 2018 17 quarters
Bridgebio Pharma Inc 1.2% 26,620,991 264.6M USD unchanged Q2 2019 14 quarters
Adaptive Biotechnologies Cor 1.0% 29,993,708 213.6M USD unchanged Q2 2019 14 quarters
Avantor Inc 0.3% 2,898,662 56.8M USD −53.0% reduced Q2 2019 14 quarters
FTV Fortive 1.6% 6,076,200 354.2M USD −48.5% reduced Q3 2019 13 quarters
Guardant Health Inc 1.0% 3,835,610 206.5M USD −14.4% reduced Q3 2019 13 quarters
Molina Healthcare Inc 0.6% 406,671 134.1M USD −14.4% reduced Q3 2019 13 quarters
CB Chubb Limited 3.0% 3,593,242 653.5M USD −4.8% reduced Q1 2020 11 quarters
TMUS T-Mobile US 2.1% 3,324,606 446.1M USD −63.7% reduced Q1 2020 11 quarters
Api Group Corp 2.1% 33,819,567 448.8M USD +0.5% increased Q2 2020 10 quarters
Royalty Pharma PLC 2.0% 10,881,594 437.2M USD −12.0% reduced Q2 2020 10 quarters
PH Parker Hannifin 2.0% 1,775,453 430.2M USD −42.2% reduced Q2 2020 10 quarters
TMO Thermo Fisher Scientific 1.4% 593,537 301.0M USD −31.2% reduced Q2 2020 10 quarters
Karuna Therapeutics Inc 1.1% 1,014,116 228.1M USD −9.4% reduced Q3 2020 9 quarters
PODD Insulet Corporation 0.6% 611,038 140.2M USD +21.4% increased Q3 2020 9 quarters
Inhibrx Inc 0.4% 5,305,866 95.2M USD unchanged Q3 2020 9 quarters
GE GE Aerospace 3.7% 12,874,144 797.0M USD +47.1% increased Q4 2020 8 quarters
META Meta Platforms 3.4% 5,351,499 726.1M USD +86.7% increased Q4 2020 8 quarters
Acadia Healthcare Company In 1.1% 2,958,932 231.3M USD −14.9% reduced Q4 2020 8 quarters
MRSH Marsh McLennan 0.7% 1,006,898 150.3M USD −64.4% reduced Q4 2020 8 quarters
NOW ServiceNow 0.6% 323,368 122.1M USD +8.7% increased Q4 2020 8 quarters
4D Molecular Therapeutics In 0.1% 3,937,914 31.7M USD unchanged Q4 2020 8 quarters
Kinnate Biopharma Inc 0.1% 1,820,462 21.8M USD unchanged Q4 2020 8 quarters
AMP Ameriprise Financial 2.1% 1,803,989 454.5M USD +52.4% increased Q1 2021 7 quarters
CRL Charles River Laboratories 0.6% 658,478 129.6M USD +19.0% increased Q1 2021 7 quarters
Zai Lab Ltd 0.4% 2,614,817 89.4M USD −20.8% reduced Q1 2021 7 quarters
Edgewise Therapeutics Inc 0.2% 4,409,146 43.4M USD +61.7% increased Q1 2021 7 quarters
Orion Acquisition Corp 0.2% 3,629,247 35.8M USD −2.0% reduced Q1 2021 7 quarters
Pharvaris N V < 0.1% 2,496,923 20.1M USD +0.2% increased Q1 2021 7 quarters
Brookfield Asset Mgmt Inc 2.8% 14,757,027 603.4M USD +21.6% increased Q2 2021 6 quarters
Intellia Therapeutics Inc 0.5% 1,889,067 105.7M USD −15.2% reduced Q2 2021 6 quarters
Day One Biopharmaceuticals I 0.1% 1,558,563 31.2M USD −16.1% reduced Q2 2021 6 quarters
Talaris Therapeutics Inc < 0.1% 3,289,617 8.7M USD unchanged Q2 2021 6 quarters
Hdfc Bank Ltd 2.6% 9,713,845 567.5M USD +5.8% increased Q3 2021 5 quarters
UBER Uber 2.0% 16,396,107 434.5M USD −1.1% reduced Q3 2021 5 quarters
Ginkgo Bioworks Holdings Inc 1.5% 101,834,126 317.7M USD +276.0% increased Q3 2021 5 quarters
Rallybio Corp 0.3% 4,194,777 60.7M USD unchanged Q3 2021 5 quarters
Biomarin Pharmaceutical Inc 2.0% 5,099,164 432.3M USD +0.9% increased Q4 2021 4 quarters
IFF International Flavors & Fragrances 1.6% 3,726,736 338.5M USD −27.2% reduced Q4 2021 4 quarters
TTWO Take-Two Interactive 1.4% 2,804,400 305.7M USD +40.2% increased Q4 2021 4 quarters
XYZ Block, Inc. 1.4% 5,311,049 292.1M USD −5.2% reduced Q4 2021 4 quarters
Roivant Sciences Ltd 1.3% 88,238,700 284.1M USD unchanged Q4 2021 4 quarters
BEKE KE Holdings 0.3% 3,895,000 68.2M USD −62.6% reduced Q4 2021 4 quarters
RIVN Rivian Automotive 0.2% 1,602,193 52.7M USD unchanged Q4 2021 4 quarters
Global E Online Ltd 0.2% 1,575,580 42.2M USD −48.3% reduced Q4 2021 4 quarters
Lianbio < 0.1% 3,564,173 7.1M USD unchanged Q4 2021 4 quarters

“Held since”: the first quarter from which the position appears in the 13F filing at every quarter end. It first appears at the end of that quarter – the filing gives neither date nor price, and trading between two quarter ends is not visible. “Or earlier”: the position was already in the first available filing (or the first one after a gap in filings). After a change of the security identifier (e.g. a renaming) the start may appear later.

Show more (up to 500) Shown: the 50 longest-held of 87 positions.

Plus 1 position in convertible bonds and bonds worth 87.9M USD as reported – not included in the weights.

Convertible bonds and bonds, principal amount as reported. They are not stock positions and therefore do not count towards the weights.

  • Guardant Health Inc principal 120.0M USD 87.9M USD

Breakdown by sector

  • Financials 16.3%
  • Health Care 15.4%
  • Technology 11.1%
  • Industrials 9.3%
  • Communication Services 6.9%
  • Consumer Discretionary 5.3%
  • Consumer Staples 3.1%
  • Materials 2.0%
  • Real Estate 0.1%
  • not in our coverage 30.6%

Sectors only for stocks we cover; the rest is grouped under “not in our coverage”.

How to read this page

  • Weight: a position’s share of the total value of all reported stock positions in this quarter – options and bonds are not counted.
  • Change: number of shares compared with the previous quarter. After a stock split we convert the previous quarter’s share count so that a split does not look like an increase; if a possible split cannot be confirmed, “–” is shown.
  • Reported value: value of the position at quarter end as reported by the investor. The portfolio may have changed since then.

All superinvestor portfolios Screener: stocks held by superinvestors

↑ ↓ select · Enter open · Esc close